The diverging trajectories of cannabis and tobacco policies in the United States: reasons and possible implications

Addiction

Volumn 113, Issue 4, 2018, Pages 595-601

  Hall, Wayne ^a,b   Kozlowski, Lynn T ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cannabis; legalization; policy; prohibition; tobacco harm reduction; tobacco smoking

Indexed keywords

CANNABIS USE; HUMAN; LEGISLATION AND JURISPRUDENCE; PUBLIC POLICY; TOBACCO USE; UNITED STATES;

HUMANS; MARIJUANA USE; PUBLIC POLICY; TOBACCO USE; UNITED STATES;

EID: 85043425429     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/add.13845     Document Type: Article

References (65)

1. Warner K. E. An endgame for tobacco? Tob Control 2013; 22: i3–5.
2. Benowitz N. L., Henningfield J. E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med 1994; 331: 123–125.
3. Family Smoking Prevention and Tobacco Control Act. 123 Stat 1783; 21 USC §321 (2009). Washington, DC: US Government Printing Office; 2009.
4. Hatsukami D. K., Benowitz N. L., Donny E., Henningfield J., Zeller M. Nicotine reduction: strategic research plan. Nicotine Tob Res 2013; 15: 1003–1013.
5. World Health Organization Study Group of Tobacco Product Regulation. Advisory note: global nicotine reduction strategy. Geneva: World Health Organization; 2015. Available at: http://www.who.int/tobacco/publications/prod_regulation/nicotine-reduction/en (accessed 17 January 2017) (Archived at http://www.webcitation.org/6ncebraw8).
6. Hall W. D., West R. Thinking about the unthinkable: a de-facto prohibition on smoked tobacco products. Addiction 2008; 103: 873–874.
7. Kozlowski L. T. Prospects for a nicotine-reduction strategy in the cigarette endgame: alternative tobacco harm reduction scenarios. Int J Drug Policy 2015; 26: 543–547.
8. Kozlowski L. T. Cigarette prohibition and the need for more prior testing of the WHO TobReg's global nicotine-reduction strategy. Tob Control 2016; https://doi.org/10.1136/tobaccocontrol-2016-052995.
9. Kozlowski L. T. Let actual markets help assess the worth of optional very-low-nicotine cigarettes before deciding on mandatory regulations. Addiction 2017; 112: 3–5.
10. McKee M., Daube M., Chapman S. E-cigarettes should be regulated. Med J Aust 2016; 204: 331.
11. Hall W. D., Gartner C., Forlini C. Ethical issues raised by a ban on the sale of electronic nicotine devices. Addiction 2015; 110: 1061–1067.
12. Kiviniemi M. T., Kozlowski L. T. Deficiencies in public understanding about tobacco harm reduction: results from a United States national survey. Harm Reduct J 2015; 12: 21.
13. Kozlowski L. T., Sweanor D. Withholding differential risk information on legal consumer nicotine/tobacco products: the public health ethics of health information quarantines. Int J Drug Policy 2016; 32: 17–23.
14. Kozlowski L. T., Sweanor D. T. Young or adult users of multiple tobacco/nicotine products urgently need to be informed of meaningful differences in product risks. Addict Behav 2017; https://doi.org/10.1016/j.addbeh.2017.01.026.
15. Federal Register. Deeming Tobacco Products to be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products. Final rule. Fed Regist 2016; 81: 28973–29106.
16. Hall W. D. U.S. policy responses to calls for the medical use of cannabis. Yale J Biol Med 2015; 88: 257–264.
17. Galston W., Dionne E. J. The new politics of marijuana legalization: why opinion is changing. Washington, DC: Governance Studies at Brookings; 2013. Available at: http://www.brookings.edu/research/papers/2013/05/29-politics-marijuana-legalization-galston-dionne (accessed 27 March 2015) (Archived at http://www.webcitation.org/6nccHn1s4).
18. Wallach P., Rauch J. Bootleggers, Baptists, Bureaucrats and Bongs: How Special Interests Will Shape Marijuana Legalization. Washington, DC: Center for Effective Public Management at Brookings; 2016. Available at: http://www.brookings.edu/research/papers/2016/06/16-marijuana-special-interests-rauch-wallach (accessed 11 August 2016) (Archived at http://www.webcitation.org/6nceopibr).
19. Barry R., Glantz S. A. A Public Health Analysis of Two Proposed Marijuana Legalization Initiatives for the 2016 California Ballot: Creating the New Tobacco Industry. San Francisco, CA: Center for Tobacco Control Research and Education, University of California, San Francisco; 2016. Available at: https://tobacco.ucsf.edu/sites/tobacco.ucsf.edu/files/u9/Public%20Health%20Analysis%20of%20Marijuana%20Initiatives%201%20Feb%202016.pdf (accessed 13 March 2016) (Archived at http://www.webcitation.org/6ncf1PGGm).
20. Hall W. D. Alcohol and cannabis: comparing their adverse health effects and regulatory regimes. Int J Drug Policy 2016; 42: 57–62.
21. MacCoun R. J. Moral outrage and opposition to harm reduction. Crim Law Philos 2013; 7: 83–98.
22. Dickson S. A. Panacea or Precious Bane: Tobacco in Sixteenth Century Literature. New York, NY: New York Public Library; 1954.
23. Gloss D., Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014; Issue 3. Art. No.: CD009270. https://doi.org/10.1002/14651858.CD009270.pub3.
24. Krishnan S., Cairns R., Howard R. Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev 2009; Issue 2. Art. No.: CD007204. https://doi.org/10.1002/14651858.CD007204.pub2.
25. Lutge E. E., Gray A., Siegfried N. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database Syst Rev 2013; Issue 4. Art. No.: CD005175. https://doi.org/10.1002/14651858.CD005175.pub3.
26. Mills R. J., Yap L., Young C. A. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev 2007; Issue 1. Art. No.: CD005029. https://doi.org/10.1002/14651858.CD005029.pub2.
27. Smith L. A., Azariah F., Lavender V. T., Stoner N. S., Bettiol S. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy. Cochrane Database Syst Rev 2015; Issue 11. Art. No.: CD009464. https://doi.org/10.1002/14651858.CD009464.pub2.
28. Farrell M., Buchbinder R., Hall W. D. Should doctors prescribe cannabinoids? BMJ 2014; 348: g2737.
29. US Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. Available at: http://www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm (accessed 29 February 2016) (Archived at http://www.webcitation.org/6ncfSI9ik).
30. Glover M., Breier B. H., Bauld L. Could vaping be a new weapon in the battle of the bulge? Nicotine Tob Res 2016; https://doi.org/10.1093/ntr/ntw278.
31. Hughes J. R. Why does smoking so often produce dependence? A somewhat different view. Tob Control 2001; 10: 62–64.
32. Powledge T. M. Nicotine as therapy. PLOS Biol 2004; 2: e404.
33. Saddleson M. L., Kozlowski L. T., Giovino G. A., Goniewicz M. L., Mahoney M. C., Homish G. G. et al. Enjoyment and other reasons for electronic cigarette use: results from college students in New York. Addict Behav 2016; 54: 33–39.
34. Lopez-Quintero C., Hasin D. S., de Los Cobos J. P., Pines A., Wang S., Grant B. F. et al. Probability and predictors of remission from life-time nicotine, alcohol, cannabis or cocaine dependence: results from the National Epidemiologic Survey on alcohol and related conditions. Addiction 2011; 106: 657–669.
35. Russell M. A. Cigarette smoking: natural history of a dependence disorder. Br J Med Psychol 1971; 44: 1–16.
36. Kozlowski L. T., Giovino G. A. Softening of monthly cigarette use in youth and the need to harden measures in surveillance. Prev Med Rep 2014; 1: 53–55.
37. Kvaavik E., von Soest T., Pedersen W. Nondaily smoking: a population-based, longitudinal study of stability and predictors. BMC Public Health 2014; 14: 123.
38. Saddleson M. L., Kozlowski L. T., Giovino G. A., Homish G. G., Mahoney M. C., Goniewicz M. L. Assessing 30-day quantity-frequency of U.S. adolescent cigarette smoking as a predictor of adult smoking 14 years later. Drug Alcohol Depend 2016; 162: 92–98.
39. Kozlowski L. T., Abrams D. B. Obsolete tobacco control themes can be hazardous to public health: the need for updating views on absolute product risks and harm reduction. BMC Public Health 2016; 16: 432.
40. Jha P., Ramasundarahettige C., Landsman V., Rostron B., Thun M., Anderson R. N. et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med 2013; 368: 341–350.
41. Nutt D. J., Phillips L. D., Balfour D., Curran H. V., Dockrell M., Foulds J. et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res 2014; 20: 218–225.
42. McNeill A., Brose L., Calder R., Hitchman S., Hajek P., McRobbie H. E-cigarettes: an evidence update: a report commissioned by Public Health England. London, UK: Public Health England; 2015. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/457102/Ecigarettes_an_evidence_update_A_report_commissioned_by_Public_Health_England_FINAL.pdf (accessed 11 August 2016) (Archived at http://www.webcitation.org/6nccyIgRv).
43. Warner K. E. The remarkable decrease in cigarette smoking by American youth: further evidence. Prev Med Rep 2015; 2: 259–261.
44. Kozlowski L. T., Warner K. E. Adolescents and e-cigarettes: objects of concern may appear larger than they are. Drug Alcohol Depend 2017; 174: 209–214.
45. Degenhardt L., Dierker L., Chiu W. T., Medina-Mora M. E., Neumark Y., Sampson N. et al. Evaluating the drug use ‘gateway’ theory using cross-national data: consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. Drug Alcohol Depend 2010; 108: 84–97.
46. Saddleson M. L., Kozlowski L. T., Giovino G. A., Hawk L. W., Murphy J. M., MacLean M. G. et al. Risky behaviors, e-cigarette use and susceptibility of use among college students. Drug Alcohol Depend 2015; 149: 25–30.
47. Vanyukov M. M., Tarter R. E., Kirillova G. P., Kirisci L., Reynolds M. D., Kreek M. J. et al. Common liability to addiction and ‘gateway hypothesis’: theoretical, empirical and evolutionary perspective. Drug Alcohol Depend 2012; 123: S3–17.
48. Levy D. T., Cummings K. M., Villanti A. C., Niaura R., Abrams D. B., Fong G. T. et al. A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products. Addiction 2017; 112: 8–17.
49. Donny E. C., Denlinger R. L., Tidey J. W., Koopmeiners J. S., Benowitz N. L., Vandrey R. G. et al. Randomized trial of reduced-nicotine standards for cigarettes. N Engl J Med 2015; 373: 1340–1349.
50. Gartner C., Hall W. Tobacco harm reduction in people with serious mental illnesses. Lancet Psychiatry 2015; 2: 485–487.
51. The Geo Team. 22nd Century Group: a lot of smoke, not enough fire. Seeking Alpha, 2014. Available at: https://seekingalpha.com/article/2454105-22nd-century-group-a-lot-of-smoke-not-enough-fire (accessed June 15 2016) (Archived at http://www.webcitation.org/6iI6OhpHj).
52. Hall W. D. What are the policy lessons of national alcohol prohibition in the United States, 1920–1933? Addiction 2010; 105: 1164–1173.
53. Reuter P., Majmundar M. K. editors. Understanding the U.S. Illicit Tobacco Market: Characteristics, Policy Context, and Lessons From International Experiences. Washington, DC: National Academies Press for the National Research Council Committee on the Illicit Tobacco Market and Committee on Law and Justice, and the Institute of Medicine Board on Population Health and Public Health Practice; 2015.
54. Belanger R. E., Akre C., Kuntsche E., Gmel G., Suris J. C. Adding tobacco to cannabis—its frequency and likely implications. Nicotine Tob Res 2011; 13: 746–750.
55. Schauer G. L., Berg C. J., Kegler M. C., Donovan D. M., Windle M. Differences in tobacco product use among past month adult marijuana users and nonusers: findings from the 2003–2012 National Survey on drug use and health. Nicotine Tob Res 2016; 18: 281–288.
56. Brandt A. The Cigarette Century: the Rise, Fall, and Deadly Persistence of the Product That Defined America. New York: Basic Books; 2007.
57. Babor T., Caetano R., Casswell S., Edwards G., Giesbrecht N., Graham K. et al. Alcohol: No Ordinary Commodity: Research and Public Policy, 2nd edn. Oxford, UK: Oxford University Press; 2010.
58. Hall W. D., Lynskey M. Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction 2016; 111: 1764–1773.
59. Hall W. D., Renström M., Poznyak V. The Health and Social Effects of Nonmedical Cannabis Use. Geneva: World Health Organization; 2016. Available at: http://www.who.int/substance_abuse/publications/msb_cannabis_report.pdf (accessed 20 May 2016) (Archived at http://www.webcitation.org/6nce8X9Zd).
60. Hall W. D. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015; 110: 19–35.
61. Hall W. D., Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374: 1383–1391.
62. National Academies of Sciences Engineering and Medicine. The Health Effects of Cannabis and Cannabinoids: the Current State of Evidence and Recommendations For Research. Washington, DC: The National Academies Press; 2017.
63. Pacula R. L., Kilmer B., Wagenaar A. C., Chaloupka F. J., Caulkins J. P. Developing public health regulations for marijuana: lessons from alcohol and tobacco. Am J Public Health 2014; 104: 1021–1028.
64. Kleiman, M. A. R. How not to make a hash out of cannabis legalization. Washington Monthly 2014 (March/April/May). Available at: http://washingtonmonthly.com/magazine/marchaprilmay-2014/how-not-to-make-a-hash-out-of-cannabis-legalization/ (accessed 19 January 2017) (Archived at http://www.webcitation.org/6nccRD1EX).
65. Courtwright D. T. A short history of drug policy or why we make war on some drugs but not on others. In: Collins J., Kitchen N., editors. Governing the Global Drug Wars. London, UK: London School of Economics and Political Science; 2012, pp. 17–25.